PNC Financial Services Group’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $35.9K | Buy |
1,107
+660
| +148% | +$25.2K | ﹤0.01% | 3531 |
|
|
2026
Q2 | $16.6K | Sell |
447
-16
| -3% | -$517 | ﹤0.01% | 3825 |
|
|
2026
Q1 | $14.7K | Sell |
463
-45
| -9% | -$1.23K | ﹤0.01% | 3782 |
|
|
2025
Q4 | $13.8K | Sell |
508
-13
| -2% | -$342 | ﹤0.01% | 3789 |
|
|
2025
Q3 | $13.5K | Buy |
521
+257
| +97% | +$5.96K | ﹤0.01% | 3780 |
|
|
2025
Q2 | $5.37K | Buy |
264
+165
| +167% | +$3.21K | ﹤0.01% | 4068 |
|
|
2025
Q1 | $1.8K | Buy |
99
+92
| +1,314% | +$2.06K | ﹤0.01% | 4366 |
|
|
2024
Q4 | $177 | Sell |
7
-238
| -97% | -$6.47K | ﹤0.01% | 4656 |
|
|
2024
Q3 | $8.33K | Sell |
245
-186
| -43% | -$7.09K | ﹤0.01% | 3826 |
|
|
2024
Q2 | $16K | Buy |
431
+39
| +10% | +$1.47K | ﹤0.01% | 3535 |
|
|
2024
Q1 | $16.5K | Sell |
392
-33
| -8% | -$1.36K | ﹤0.01% | 3487 |
|
|
2023
Q4 | $16.9K | Buy |
425
+33
| +8% | +$971 | ﹤0.01% | 3459 |
|
|
2023
Q3 | $10.8K | Sell |
392
-240
| -38% | -$7.52K | ﹤0.01% | 3657 |
|
|
2023
Q2 | $21.4K | Buy |
632
+148
| +31% | +$4.99K | ﹤0.01% | 3463 |
|
|
2023
Q1 | $17.4K | Hold |
484
| – | – | ﹤0.01% | 3501 |
|
|
2022
Q4 | $21.6K | Buy |
484
+397
| +456% | +$14.2K | ﹤0.01% | 3372 |
|
|
2022
Q3 | $2K | Sell |
87
-13
| -13% | -$399 | ﹤0.01% | 4147 |
|
|
2022
Q2 | $3K | Buy |
+100
| New | +$2.9K | ﹤0.01% | 4082 |
|
|
2021
Q1 | – | Sell |
-1,000
| Closed | -$18K | – | 4114 |
|
|
2020
Q4 | $18K | Hold |
1,000
| – | – | ﹤0.01% | 3338 |
|
|
2020
Q3 | $15K | Buy |
+1,000
| New | +$11.7K | ﹤0.01% | 3297 |
|
|
2019
Q4 | – | Sell |
-79
| Closed | – | – | 3998 |
|
|
2019
Q3 | $0 | Hold |
79
| – | – | ﹤0.01% | 3998 |
|
|
2019
Q2 | $0 | Hold |
79
| – | – | ﹤0.01% | 4023 |
|
|
2019
Q1 | $0 | Sell |
79
-1
| -1% | – | ﹤0.01% | 4039 |
|
|
2018
Q4 | $0 | Hold |
80
| – | – | ﹤0.01% | 4052 |
|
|
2018
Q3 | $1K | Hold |
80
| – | – | ﹤0.01% | 3992 |
|
|
2018
Q2 | $1K | Hold |
80
| – | – | ﹤0.01% | 4011 |
|
|
2018
Q1 | $3K | Hold |
80
| – | – | ﹤0.01% | 3949 |
|
|
2017
Q4 | $3K | Sell |
80
-67
| -46% | -$2.87K | ﹤0.01% | 3917 |
|
|
2017
Q3 | $6K | Hold |
147
| – | – | ﹤0.01% | 3788 |
|
|
2017
Q2 | $5K | Hold |
147
| – | – | ﹤0.01% | 3773 |
|
|
2017
Q1 | $8K | Sell |
147
-53
| -27% | -$2.76K | ﹤0.01% | 3559 |
|
|
2016
Q4 | $11K | Sell |
200
-967
| -83% | -$55K | ﹤0.01% | 3403 |
|
|
2016
Q3 | $71K | Sell |
1,167
-36
| -3% | -$2.24K | ﹤0.01% | 2508 |
|
|
2016
Q2 | $79K | Sell |
1,203
-28
| -2% | -$1.78K | ﹤0.01% | 2490 |
|
|
2016
Q1 | $70K | Buy |
1,231
+333
| +37% | +$37.5K | ﹤0.01% | 2554 |
|
|
2015
Q4 | $211K | Buy |
898
+75
| +9% | +$16.4K | ﹤0.01% | 1879 |
|
|
2015
Q3 | $130K | Sell |
823
-52
| -6% | -$14.7K | ﹤0.01% | 2206 |
|
|
2015
Q2 | $331K | Buy |
875
+18
| +2% | +$7.15K | ﹤0.01% | 1717 |
|
|
2015
Q1 | $358K | Buy |
857
+7
| +0.8% | +$2.5K | ﹤0.01% | 1654 |
|
|
2014
Q4 | $233K | Buy |
850
+17
| +2% | +$4.23K | ﹤0.01% | 1793 |
|
|
2014
Q3 | $162K | Hold |
833
| – | – | ﹤0.01% | 1912 |
|
|
2014
Q2 | $204K | Buy |
833
+66
| +9% | +$14.9K | ﹤0.01% | 1735 |
|
|
2014
Q1 | $203K | Hold |
767
| – | – | ﹤0.01% | 1728 |
|
|
2013
Q4 | $278K | Hold |
767
| – | – | ﹤0.01% | 1548 |
|
|
2013
Q3 | $407K | Buy |
767
+534
| +229% | +$183K | ﹤0.01% | 1307 |
|
|
2013
Q2 | $55K | Hold |
233
| – | – | ﹤0.01% | 2226 |
|
Other funds holding CLDX
KCM
BBA
PNC Financial Services Group's CLDX Position: Q3 2026 in Review
PNC Financial Services Group increased its Celldex Therapeutics (CLDX) stake by 148% in Q3 2026, buying an estimated $25.2K and bringing the position to 1,107 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3531.
PNC Financial Services Group first reported a position in CLDX in Q2 2013 and has held it in 46 quarters since. The position peaked at $407K in Q3 2013. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- PNC Financial Services Group held 1,107 shares of Celldex Therapeutics worth $35.9K as of Q3 2026.
- PNC Financial Services Group bought 660 Celldex Therapeutics shares in Q3 2026, an estimated $25.2K.
- Celldex Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3531 holding.
- PNC Financial Services Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 46 quarters since.
- PNC Financial Services Group's Celldex Therapeutics position peaked at $407K in Q3 2013.
- 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.